Group 1 - The company, WuXi AppTec Co., Ltd. (2268.HK), announced two fundraising arrangements totaling HKD 27.14 billion (USD 3.48 billion) [1] - The company plans to issue up to 22.277 million new shares at HKD 58.85 per share, representing a discount of approximately 4%, with a net amount of about HKD 1.3 billion, accounting for approximately 1.82% of the enlarged share capital [1] - The company has entered into a subscription agreement with its controlling shareholder, WuXi Biologics (2269.HK), which will subscribe for 24.134 million new shares at the same price, representing approximately 1.93% of the enlarged share capital, with a net amount of about HKD 1.414 billion [1] Group 2 - Approximately 90% of the proceeds will be used to expand the capabilities and capacity for bioconjugate drug services, including the construction of a new base in Singapore, expansion of the Wuxi facility, and potential overseas expansion [1] - The remaining 10% of the proceeds will be allocated for working capital and general corporate purposes [1] - Following the completion of these transactions, the shareholding of WuXi Biologics will increase from 49.81% to 50.78% [1] Group 3 - The stock price of WuXi AppTec opened higher on Wednesday, reaching HKD 64.65 at midday, an increase of 5.46% [2]